Table 1 |
|||
|
Baseline characteristics of subjects in placebo and active-drug arms of a trial of interferon-β-1a in patients with rheumatoid arthritis |
|||
|
Characteristic |
Placebo (n = 6) |
Drug (n = 16) |
P valuea |
|
|
|||
|
Mean age (range) |
53 (39–69) |
54 (35–72) |
0.80 |
|
Women (%) |
6 (100) |
13 (81) |
0.53 |
|
Mean weight in pounds (range) |
157 (109–211) |
164 (117–289) |
0.62 |
|
Mean number of tender joints (range) |
25 (14–41) |
20 (8–45) |
0.40 |
|
Mean number of swollen joints (range) |
19 (6–40) |
16 (7–34) |
0.68 |
|
Mean HAQ Disability Index (0–3) (SD) |
1.45 (0.53) |
1.36 (0.72) |
0.76 |
|
Mean C-reactive protein (SD) |
1.6(1.1) |
2.4 (1.7) |
0.31 |
|
Mean physician's global assessment (0–10) (SD) |
5.8(2.2) |
5.6 (2.0) |
0.85 |
|
Mean patient's global self assessment (0–10) (SD) |
5.6 (2.5) |
5.9 (2.7) |
0.87 |
|
Mean pain VAS (0–10) (SD) |
5.8 (1.2) |
5.8 (2.6) |
0.97 |
|
Number of patients on DMARDS (%) |
2 (33%) |
13 (81%) |
0.05 |
|
Number of patients on NSAIDs (%) |
2 (33%) |
12 (75%) |
0.09 |
|
Mean number of DMARDS (range) |
1.3 (0–3) |
0.9 (0–2) |
0.37 |
|
Number of patients on prednisone |
4 (67%) |
12 (75%) |
0.54 |
|
Mean dose (mg) of prednisone (range) |
4.7 (0–10) |
5.2 (0–10) |
0.82 |
|
Baseline disease duration (years) (range) |
10.1 (0.2–29.4) |
14.2 (0.4–33.8) |
0.38 |
|
|
|||
|
aP values are for one-tailed t-tests and Fisher's exact test, as appropriate. DMARD, disease-modifying antirheumatic drug; HAQ, Health Assessment Questionnaire; NSAID, nonsteroidal anti-inflammatory drug; SD, standard deviation; VAS, Visual Analog Scale. |
|||
|
Genovese et al. Arthritis Res Ther 2004 6:R73 doi:10.1186/ar1026 |
|||
